Evidence map›Paper›PMID 28111599›Full record

ArticleChemical science2016

Nickel-Catalyzed C-3 Direct Arylation of Pyridinium Ions for the Synthesis of 1-Azafluorenes.

Jean-Nicolas Desrosiers, Xudong Wei, Osvaldo Gutierrez, Jolaine Savoie, Bo Qu, Xingzhong Zeng, Heewon Lee, Nelu Grinberg, Nizar Haddad, Nathan K Yee and 4 more

Abstract read
In one paragraph

Article in Chemical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. On the Nature of C(spJournal of the American Chemical Society · 2020
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jean-Nicolas DesrosiersDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Xudong WeiDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Osvaldo GutierrezDepartment of Chemistry, University of Pennsylvania, Philadelphia, PA 19104-6323, USA.
Jolaine SavoieDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Bo QuDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Xingzhong ZengDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Heewon LeeDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Nelu GrinbergDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Nizar HaddadDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Nathan K YeeDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Frank RoschangarDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Jinhua J SongDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Marisa C KozlowskiDepartment of Chemistry, University of Pennsylvania, Philadelphia, PA 19104-6323, USA.
Chris H SenanayakeDepartment of Chemical Development US, Boehringer-Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Ridgefield, CT, 06877, USA.

Funding

Computational Methods for Selective CatalysisR01GM087605 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI KOZLOWSKI, MARISA C · 2010 to 2019
$2.4M
NIGMS NIH HHS R01 GM087605
6 · The paper itself

Abstract

The direct arylation of pyridine substrates using non-precious catalysts is underdeveloped but highly desirable due to its efficiency to access important motifs while being extremely cost-effective. The first nickel-catalyzed C-3 direct arylation of pyridine derivatives to provide a new approach to valuable 1-azafluorene pharmacophore frameworks was developed. This transformation is accomplished using air-stable nickel catalyst precursors combined with phenanthroline ligands and tolerates a variety of substituents. Computational studies suggest facile oxidative addition via the pyridinium form, deprotonation, and a subsequent carbo-nickelation cyclization. Nickel homolysis/recombination permits isomerization to the stereochemical array needed for the final elimination.

Identifiers

PMID28111599
PMCPMC5245920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.